BMT and Immunotherapies for Pediatric Leukemia
Current and novel treatments and financial implications
Jointly planned by the National Marrow Donor Program®/Be The Match® and the Aplastic Anemia and MDS International Foundation.
Release date: June 10, 2019
Expiration date: June 10, 2021
In this recorded webinar, you'll learn that bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.
- Define current BMT and immunotherapy agent outcomes with mechanisms of action used to treat pediatric leukemia
- List the common side effects associated with immunotherapy and the supportive care needs for monitoring and educating patients and families
- Examine financial burdens associated with BMT and immunotherapy
- Identify educational resources available to assist in addressing a family’s information and financial needs
The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for pediatric patients with leukemia.
Vicki Szenes, MS, RN, CPNP, CPHON®
Pediatric Nurse Practitioner
Memorial Sloan-Kettering Cancer Center
Victoria Szenes graduated from Binghamton University with a Bachelor of Art in Anthropology and a minor in the School of Management. She then received her Bachelor of Science in Nursing and later her Master of Science in Nursing in the Pediatric Nurse
Practitioner program, both from Columbia University. She began her career as a clinical nurse in 2008 on the Pediatric Hematology/Oncology unit at Columbia- Presbyterian. After receiving her NP license she worked as a research nurse practitioner for
the pediatric oncology team at Columbia University. In 2013, she joined the Pediatric Bone Marrow Transplant team at Memorial Sloan Kettering Cancer Center and currently serves as a clinical trials nurse practitioner.
Meghan Wellenbrink, BSN, RN, CPHON
CAR-T Cell Clinical Nurse Coordinator
Memorial Sloan-Kettering Cancer Center
Meghan Wellenbrink is the CAR-T Cell Clinical Nurse Coordinator at Memorial Sloan-Kettering Cancer Center. I have been a nurse on the pediatric unit at Memorial for over seven years, the last of which has been primarily with the Bone Marrow Transplant Team focusing on the intake and management of CAR T Cell patients.
|Vicki Szenes, MS, RN, CPNP CPHON
|Meghan Wellenbrink BSN, RN, CPHON
|Opportunity for Questions & Answer||10 minutes|
Hematology, oncology and BMT nurses; hematology, oncology and BMT social workers at intermediate to advanced levels of practice, experience and licensure; transplant center coordinators; payer case managers and other allied health professionals.
Accreditation and Certification
Nurses: The National Marrow Donor Program is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Up to 1.0 contact hours may be claimed for this educational activity.
Social Workers: National Marrow Donor Program, #1386, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. National Marrow Donor Program maintains responsibility for the program. ASWB Approval Period: 08/10/2016 - 08/10/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits.
Social workers participating in this course will receive 1.0 clinical continuing education clock hours.
Laboratory Professionals: The NMDP is approved as a provider of continuing education in the clinical laboratory sciences through the ASCLS PACE Program. ASCLS PACE® 1861 International Drive, Suite 200, McLean, VA 22102. Up to 1.0 contact hours may be claimed for program #115-009-19.
Participants must complete and submit the evaluation for the activity in order to receive a continuing education certificate or a certificate of completion.
If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email email@example.com.
1. Yaniv I, Krauss AC, Beohu E, et al. Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children. Biol Blood Marrow Transplant. 2018; 24:1629-1642.
2. Im HJ. Current treatment for pediatric acute myeloid leukemia. Blood Res. 2018; 53(1):1-2.
3. D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http://www.cibmtr.org
4. Warren CB. Immunotherapy in Pediatric Oncology. Clin J Oncol Nurs. 2018;22(6):649-655.
5. Bayer V, Amaya B, Baniewicz D, et al. Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice. Clin J Oncol Nurs. 2017; 21(2):13-21.
7. Bona K, London WB, Guo D, et al. Prevalence and Impact of Financial Harship among New England Pediatric Stem cell Transplantation Families. Biol Blood Marrow Transplant. 2015; 21:312-318.
8. Spencer JC, Samuel CA, Rosenstein DL, et al. Oncology navigators’ perceptions of cancer- related financial burden and financial assistance resources. Supportive Care in Cancer. 2018; 26(4):1315–1321.